Dazodalibep Meets ESSDAI Primary End Point in Phase 3 Sjögren's TrialByVictoria JohnsonSeptember 22nd 2026
Rozanolixizumab Has Mixed Phase 2A Results in Severe FibromyalgiaByVictoria JohnsonSeptember 21st 2026
POETYK PsA-2: Deucravacitinib Shows Durable Efficacy Through 2 YearsByVictoria JohnsonSeptember 17th 2026